Adalimumab 80 mg every 2, 3, and 4 weeks improved the severity of psoriasis in a small study of patients with psoriasis. The findings from this study were published in Dermatologic Therapy.

Patients with psoriasis from 2 different hospitals in Spain were included in this retrospective study (n=11; mean age, 50.9 years). The patients received different administration regimens of adalimumab 80 mg. A cohort of 27.3% of patients received adalimumab 80 mg injection every 3 weeks. Other patient groups received therapy every 2 weeks (36.4%) or every 4 weeks (36.4%).

In total, 63.6% of patients underwent intensified treatment with adalimumab 80 every 2 or 3 weeks. The average treatment duration was 32 weeks (range, 16-55 weeks). The investigators examined efficacy of treatment using the psoriasis area severity index (PASI) as a guide.

The average initial PASI value was 3.16. At the end of the study period, 72.7% of patients experienced an improvement in PASI. The final mean PASI was 0.94, and the mean improvement in absolute PASI was 2.23. All of the patients who had an initial PASI of 0 (18.2%) maintained their PASI value by the end of the study.


Continue Reading

In the patients who were treated with adalimumab 80 mg every 4 weeks (36.4%), the PASI improved from a mean initial value of 1.2 to a mean final value of 1.05 (mean improvement in absolute PASI, 0.15). In the group of patients who were treated with intensified adalimumab 80 mg, PASI improved from an initial 4.29 to a final 0.87 (mean improvement in absolute PASI, 3.41). None of the patients reported an adverse event throughout the study period.

Limitations of the study included its small sample size as well as its retrospective nature, which the investigators said prevented their ability to obtain conclusive information about this therapy.

Based on their findings, the investigators of this study support an every 2-, 3-, or 4-week administration pattern of adalimumab 80 mg “in those patients with psoriasis or psoriatic arthropathy” and/or in those “who want a maintenance of the clinical response with a lower dose frequency or lower number of injections.”

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.

Reference

Sabater-Abad J, Matellanes-Palacios M, Bou-Boluda L, et al. Efficacy and safety of adalimumab 80 mg in the treatment of psoriasis: a bicentric retrospective study [published online April 3, 2020]. Dermatol Ther. doi: 10.1111/dth.13369